{
    "key_points": [
        "The FDA has authorized a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 and older, those 18-64 at high risk of severe COVID-19, and those 18-64 with frequent exposure to SARS-CoV-2.",
        "This authorization is based on scientific evidence and advice from the FDA's advisory committee.",
        "The booster dose is authorized for use at least six months following completion of the primary series.",
        "The vaccine referred to is the same formulation as the FDA-approved Comirnaty and can be used interchangeably.",
        "The decision was supported by safety and immune response data from the original clinical trial and real-world data.",
        "The authorization aims to enhance protection against COVID-19 amidst the Delta variant surge.",
        "Common side effects of the booster dose include pain at the injection site, fatigue, headache, muscle or joint pain, chills, and swollen lymph nodes.",
        "FDA considered the vaccineâ€™s waning efficacy over time as a factor for booster approval.",
        "The booster dose has been authorized under emergency use authorization (EUA).",
        "EUA allows for the use of medical products during public health emergencies."
    ],
    "spokespersons": [
        "Janet Woodcock, M.D. (Acting FDA Commissioner)",
        "Peter Marks, M.D., Ph.D. (Director of FDA\u2019s Center for Biologics Evaluation and Research)"
    ],
    "article_type": "government agency statement",
    "dateline": "Today",
    "audience": "general public",
    "stance": "neutral"
}